1. Labroo RB *et al.* Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. *Drug Metabolism & Disposition* 1997;**25**(9):1072-80.

2. Koehntop DE and Rodman JH. Fentanyl Pharmacokinetics in Patients Undergoing Renal Transplantation. *Pharmacotherapy* 1997;**17**(4):746-752

3. Davis PJ *et al.* Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. *Anesth Analg* 1988;**67**(3):268-71.

4. Bastani B and Jamal JA. Removal of morphine but not fentanyl during haemodialysis. *Nephrol Dial Transplant* 1997;**12**:2804.

5. Joh J *et al*. Nondialyzability of Fentanyl with high-Efficiency and High-Flux Membranes. *Anesth Analg* 1998;**86**:447.

6. Kaiko RF *et al.* Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. *Clin Pharmacol Ther* 1996;**59**:52-61.

7. Heiskanen T *et al.* Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. *Clin Pharmacol Ther* 1998;**64**:603-11.

8. Kirvela M *et al.* The Pharmacokinetics of Oxycodone in Uremic Patients Undergoing Renal Transplantation. *J Clin Anaeasthesia* 1996;**8**:13-18.

9. Kreek MJ *et al.* Drug Interactions with Methadone. *Ann N.Y. Acad. Sci* 1976;**281**:350-370.

10. Kreek MJ *et al.* Methadone Use in Patients with Chronic Renal Disease. *Drug and Alcohol Dependence* 1980;**5**:197-205.

11. Furlan V *et al*. Methadone is poorly removed by haemodialysis. *Nephrology Dialysis Transplantation* 1999;**14**(1):254-5.

12. Smith MT. Neuroexcitatory Effects of Morphine and Hydromorphone: Evidence for Implicating the 3-Glucuronide Metabolites. *Clinical and Experimental Pharmacology and Physiology* 2000;**27**:524-528.

13. Fainsinger R *et al.* Palliative Care Round: Cognitive Failure and Coma After Renal Failure in a Patient Receiving Captopril and Hydromorphone. *J Palliative Care* 1993;**9**(1):53-55.

14. Lee MA *et al*. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. *Palliat Med* 2001;**15**:26-34.

15. Durnin C *et al.* Pharmacokinetics of Oral Immediate-Release Hydromorphone (Dilaudid® IR) in Subjects with Renal Impairment. *Proc.West. Pharmacol. Soc* 2001;**44**:81-82.